Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

napp pharmacuticals limited uk, united kingdom - fluticasone propionate,formoterol fumarate - pressurised inhalation, suspension - 0.05,0.005 mg,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

napp pharmacuticals limited uk, united kingdom - fluticasone propionate,formoterol fumarate - pressurised inhalation, suspension - 0.25,0.01 mg,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

napp pharmacuticals limited uk, united kingdom - fluticasone propionate,formoterol fumarate - pressurised inhalation, suspension - 0.125,0.005 mg,

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - fluticasone propionate, quantity: 40 mg; formoterol fumarate dihydrate, quantity: 1.6 mg - inhalation, pressurised - excipient ingredients: ethanol absolute; sodium cromoglycate; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - fluticasone propionate, quantity: 20 mg; formoterol fumarate dihydrate, quantity: 0.8 mg - inhalation, pressurised - excipient ingredients: sodium cromoglycate; ethanol absolute; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - formoterol fumarate dihydrate, quantity: 0.8 mg; fluticasone propionate, quantity: 8 mg - inhalation, pressurised - excipient ingredients: ethanol absolute; sodium cromoglycate; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation - 125microgram/1dose ; 5microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation - 250microgram/1dose ; 10microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation - 50microgram/1dose ; 5microgram/1dose

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.